Antibody-drug conjugates in treating older patients suffering from cancer: what is the real value?
Immunoconjugates
efficacy
immunotherapy
monoclonal antibody
older population
toxicity
Journal
Human vaccines & immunotherapeutics
ISSN: 2164-554X
Titre abrégé: Hum Vaccin Immunother
Pays: United States
ID NLM: 101572652
Informations de publication
Date de publication:
02 12 2021
02 12 2021
Historique:
pubmed:
4
12
2021
medline:
19
4
2022
entrez:
3
12
2021
Statut:
ppublish
Résumé
Immunotherapeutic drugs and target therapies have represented an epochal change in treating cancer patients. They represent an attractive option in oncologists' armamentarium, particularly if we consider the optimal balance between efficacy and toxicity. As a step forward, immuno- and target-therapies have merged intending to improve efficacy: antibody-drug conjugates ensure the perfect combination. They allow the delivery of large amounts of drugs to the target with a limited 'off-target' effect and a low rate of adverse events. These aspects could make immunoconjugates palatable as the first choice for fragile patients, but solid evidence does not exist on the use of these drugs in this population type, especially older people.
Identifiants
pubmed: 34856865
doi: 10.1080/21645515.2021.1999711
pmc: PMC8903970
doi:
Substances chimiques
Antineoplastic Agents
0
Immunoconjugates
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5575-5578Références
JAMA Oncol. 2018 Sep 1;4(9):1214-1220
pubmed: 29955792
J Clin Oncol. 2019 Oct 10;37(29):2601-2609
pubmed: 31442103
Lancet Oncol. 2016 Jun;17(6):e254-e262
pubmed: 27299281
J Clin Oncol. 2013 Mar 20;31(9):1157-63
pubmed: 23382472
Clin Cancer Res. 2017 Oct 1;23(19):5711-5719
pubmed: 28679770
Lancet Oncol. 2014 Jun;15(7):689-99
pubmed: 24793816
Cancer J. 2015 Sep-Oct;21(5):357-64
pubmed: 26389758
Clin Cancer Res. 2019 Jan 1;25(1):64-72
pubmed: 30206164
JAMA Oncol. 2020 Feb 1;6(2):196-204
pubmed: 31697365
Lancet Oncol. 2021 Jun;22(6):779-789
pubmed: 33961795
J Clin Oncol. 2021 Jul 1;39(19):2115-2127
pubmed: 34043444
N Engl J Med. 2020 Jun 18;382(25):2419-2430
pubmed: 32469182
Lancet Oncol. 2020 Oct;21(10):1283-1295
pubmed: 33002436
Lancet Oncol. 2017 May;18(5):640-653
pubmed: 28343975
N Engl J Med. 2020 Feb 13;382(7):610-621
pubmed: 31825192
Breast Cancer Res Treat. 2018 Sep;171(2):371-381
pubmed: 29850984
N Engl J Med. 2021 Mar 25;384(12):1125-1135
pubmed: 33577729
CA Cancer J Clin. 2021 Jan;71(1):78-92
pubmed: 33002206
Lancet Oncol. 2017 Jun;18(6):743-754
pubmed: 28526538
J Clin Oncol. 2020 Jun 10;38(17):1887-1896
pubmed: 32058843
Asia Pac J Clin Oncol. 2020 Feb;16(1):5-13
pubmed: 31721447
Ann Oncol. 2020 Dec;31(12):1709-1718
pubmed: 32946924
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
Ann Oncol. 2021 Jun;32(6):746-756
pubmed: 33741442
JAMA Oncol. 2020 Aug 1;6(8):1203-1209
pubmed: 32584367
Lancet Oncol. 2021 Jun;22(6):872-882
pubmed: 33991512
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
J Thorac Oncol. 2018 Feb;13(2):273-279
pubmed: 29313813
Eur J Cancer. 2019 Mar;109:92-102
pubmed: 30708264
J Clin Oncol. 2014 May 10;32(14):1437-44
pubmed: 24733796
N Engl J Med. 2021 Apr 22;384(16):1529-1541
pubmed: 33882206
J Clin Oncol. 2017 Jul 1;35(19):2141-2148
pubmed: 28291390